Catherine Boutsikakis on The Complexities of Hemophilia
Catherine Boutsikakis, Managing Pharmacist – Patient Pharmacy at Cure 4 The Kids Foundation, shared on LinkedIn:
”Thank you Pharmacy Times for the opportunity to discuss the complexities of hemophilia, new treatments available, and the impact on patients and families.”
Watch the full discussion here.
Hemophilia is classified as mild, moderate, or severe based on clotting factor activity, which determines its clinical presentation.
Severe hemophilia is characterized by spontaneous bleeding, especially into joints and muscles, often resulting in chronic pain, limited mobility, and progressive joint damage.
Moderate hemophilia typically leads to bleeding after minor injuries, whereas mild cases usually bleed only with significant trauma or surgical procedures.
Recognizing this spectrum helps clinicians anticipate complications, individualize treatment strategies, and reduce long-term morbidity while preserving quality of life.”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 13:36Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference